Document is current
Any future updates will be listed below
-
Authors
Newson, Rachel S. https://orcid.org/0000-0002-2653-5797
Divino, Victoria https://orcid.org/0000-0001-5555-7912
Boye, Kristina S. https://orcid.org/0000-0002-5953-5929
Chen, Justin https://orcid.org/0009-0002-7960-9697
DeKoven, Mitch https://orcid.org/0000-0001-9346-6202
Vallarino, Carlos https://orcid.org/0000-0002-0929-2260
Ranta, Kari https://orcid.org/0009-0006-4126-3714
Mount, Julie E. https://orcid.org/0000-0003-2185-151X
-
Funding
Funding for this research was provided by:
Eli Lilly and Company, Indianapolis, US
- License Information
-
More Information
Article History
Received: 19 December 2023
Accepted: 4 April 2024
First Online: 29 April 2024
Declarations
:
: Rachel S. Newson, Kristina S. Boye, Carlos Vallarino, Kari Ranta, and Julie E. Mount are employees and shareholders of Eli Lilly. Victoria Divino, Justin Chen, and Mitch DeKoven are employees of IQVIA, which received consulting fees from Eli Lilly for this study.
: This study involved a retrospective analysis of de-identified data from several countries. Ethical review approval was obtained as required in Spain from the Clinical Research Ethics Committee of the Hospital Clinic de Barcelona (reference no. HCB/2022/0311) and in the UK from the Scientific Review Committee (SRC; reference no. 22SRC017). In France, the study was compliant with reference methodology MR-004 from the Commission Nationale Informatique & Libertés (CNIL), The French Data Protection Agency. Therefore, a submission to CNIL was not required, but a Privacy Impact Assessment was completed and registered. Ethics approval was not required for the analysis of the de-identified data in the other countries. IQVIA had permission to access and analyze the data in each country. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.
